Advertisement

Topics

Latest "Global Magnesium Sulfate Market Research Report Forecast 2017" News Stories

11:47 EDT 19th March 2019 | BioPortfolio

Here are the most relevant search results for "Global Magnesium Sulfate Market Research Report Forecast 2017" found in our extensive news archives from over 250 global news sources.

More Information about Global Magnesium Sulfate Market Research Report Forecast 2017 on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Global Magnesium Sulfate Market Research Report Forecast 2017 for you to read. Along with our medical data and news we also list Global Magnesium Sulfate Market Research Report Forecast 2017 Clinical Trials, which are updated daily. BioPortfolio also has a large database of Global Magnesium Sulfate Market Research Report Forecast 2017 Companies for you to search.

Showing "Global Magnesium Sulfate Market Research Report Forecast 2017" News Articles 1–25 of 53,000+

Tuesday 19th March 2019

JPJ Group plc (JPJ) - International continues to drive growth

Edison Investment Research - Travel & Leisure - JPJ Group plc: Driven by an impressive 42% organic growth in the Vera&John division, JPJ reported FY18 revenue growth of 10% to £319.6m with an EBITDA margin of 35.3%. International now comprises 43% of revenues and we expect this to increase as the company diversifies away from the UK. Cash generation remains strong and adjusted net debt/EBITDA...


DeA Capital (DEA) - Platform developments and AUM growth

Edison Investment Research - Financials - DeA Capital: DeA Capital performed well in FY18 despite turbulent financial markets, developing its alternative asset management platform and growing AUM. Minority interests have been eliminated and net asset value grew. Strong cash flow continues, driven by net distributions from maturing fund investments, sufficient to fund reinvestment and strong distri...

MyBucks (MBC) - Rapid expansion calls for new capital

Edison Investment Research - Financials - MyBucks: MyBucks’s (MBC’s) H119 results reveal a continuation of solid loan book expansion driven by both organic growth (especially in the banking business) and acquisitions (including Capfin and Pride). As the company is still loss making at the bottom line and generates negative operating cash flows, growth has been facilitated by both highe...


Focusrite (TUNE) - A solid first-half performance

Edison Investment Research - Consumer Support Services - Focusrite: Focusrite has reported solid H119 revenue growth, reflecting particularly strong performance in Europe and for its Focusrite ranges globally. We leave forecasts unchanged, recognising the macroeconomic challenges in H2 arising from US tariffs and Brexit. The company is actively seeking opportunities to use its substantial net cash...

PureCircle (PURE) - Growing pains

Edison Investment Research - Consumer Support Services - Food & Drink - PureCircle: PureCircle’s H119 results highlight the ongoing evolution in the company: sales declined 5%, partly due to phasing of deliveries, but also due to adoption of the superior-tasting, higher-margin Reb M product cannibalising the base business. Gross margins were up 240bp as a result of Reb M contributing positiv...

Invesco Asia Trust (IAT) - Disciplined Asia specialist, solid long-term returns

Edison Investment Research - Investment trusts - Invesco Asia Trust: Invesco Asia Trust (IAT) aims to provide significant capital returns over the long-term through investing in listed companies in Asia. It follows a rigorous bottom-up investment process with few constraints, to build a relatively concentrated 50–70 stock portfolio representing the manager’s highest-conviction ideas ov...

Envirotainer Opens RAP e2 and RKN e1 Station in Mumbai, India

UPPLANDS VASBY, Sweden, March 19, 2019 /PRNewswire/ -- Envirotainer, the global market leader in secure cold chain solutions for air transport of pharmaceuticals, today announced that they are expanding their network of stations supporting their state-of-the-art e-technology containers, namely the RKN e1 and RAP e2, by adding Mumbai (BOM), India, to the list. "India is probably the fast...

Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases

Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune infla...

FDA Places Partial Clinical Hold on AbbVie’s Trials Evaluating Venetoclax in Multiple Myeloma

NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating venetoclax (VENCLEXTA®/VENCLYXTO®) for the investigational treatment of multiple myeloma. The partial clinical hold follows a revi...

Better Therapeutics Publishes New Study Demonstrating Rapid Reduction in Blood Pressure Among Hypertensive Adults

Mean systolic blood pressure reduction was -11.5mmHg in systolic and -5.9mmHg in diastolic, with 90% of participants lowering blood pressure from baseline. SAN FRANCISCO (PRWEB) March 19, 2019 Today, Better Therapeutics, a company developing prescription digital therapeutics for the treatment of severe cardiometabolic diseases, announced the publication of its latest peer-reviewed clinical study ...

Researchers Find Genomic Testing Associated with Significantly Lower Health Care Costs in High-Risk Breast Cancer Patients

PLYMOUTH MEETING, Pa., March 19, 2019 /PRNewswire/ — New research from Duke University, published in the March 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network, provides evidence that genomic recurrence score (RS) testing using the 21-gene assay is associated with decreased cancer care costs in real-world practice among certain patients with breast cancer …

Multiple Myeloma-Causing Plasma Cells Show Intense Uptake of Intravenous Liposomal Curcumin as Reported by SignPath Pharma, Inc. in Paper Published in the Cancer Research Journal “Anticancer Research”

SignPath Pharma, Inc. reported in the March issue of Anticancer Research* that its proprietary intravenous liposomal curcumin (LipoCurc™) concentrates very intensely in the malignant plasma cells that cause

Almost 4 Million Americans Are CBD Users; Segment Has a Health-Focused View of Cannabis

MRI-Simmons’ syndicated National Cannabis Study provides unprecedented learning on marijuana users and avoiders The hemp-derived oil known as CBD is bringing cannabis to the mainstream, from CBD “shots” at coffee shops to edible CBD gummy bears sold at convenience stores. Newly released research from MRI-Simmons shows that people who buy CBD item...

New Research Highlights National Need for Recreational Activities to Support Children Facing Life-Threatening Illnesses

Growing national non-profit A Kid Again partners with Nationwide Children’s Hospital to gain valuable insights on children facing life-threatening illnesses COLUMBUS, Ohio (PRWEB) March 19, 2019 A Kid Again, a national non-profit organization that provides year-round recreational adventures to children and families dealing with life-threatening illnesses, announced today the results of a partne...

Global Specialty Injectable Generics Market to Surpass US$ 75.7 Billion by 2026 – Coherent Market Insights

According to Coherent Market Insights, the global specialty injectable generics market was valued at US$ 31,300 million in 2017, and is projected to exhibit a CAGR of 10.4% over the forecast period (2018 – 2026). Key Trends and Analysis of the Specialty Injectable Generics Market: Increasing prevalence of chronic diseases such as cancer...

Pfizer Invites Public to View and Listen to Webcast of April 30 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, April 30, 2019. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2019 Performance Report, to be issued that morning. To vie...

STAT Plus: Pharmalittle: Bristol and Starboard duel over Celgene deal; one in five adults ask doctors for cheaper meds

One in five U.S. adults prescribed medicines say they have asked their doctor for a cheaper option, a CDC report says.

Alcohol Dependency Curbed by Reversibly Inhibiting Specific Neurons

Scripps Research scientists have succeeded in switching off addiction-like behaviors and reducing physical withdrawal symptoms in alcohol-dependent rats, by using a laser-based technique known as optogenetics to reversibly disable a specific set of neurons in the brain. The findings could lead to new targeted drug treatments or gene therapy approaches to treating alcohol abuse disorder in people. ...

SunLink Health Systems, Inc. Completes Sale of Parkside Ellijay Nursing Home and Real Estate

SunLink Health Systems, Inc. (NYSE AMERICAN: SSY) today announced that its subsidiary, Southern Health Corporation of Ellijay, Inc., has completed the sale of its Parkside Ellijay Nursing Home and related real estate for approximately $7,300,000. The company said the net proceeds of approximately $6,400,000 will be retained for working capital and general ...

Sheba Medical Center to Collaborate with Lonza Pharma on State-of-the-Art "Cocoon" Platform to Aid Cancer Patients' Access to Life-Saving CAR-T Immunotherapy Treatments

Israel’s Sheba Medical Center, Tel HaShomer and Swiss-based Lonza Pharma begin collaboration to assess automated CAR-T cell therapy manufacturing at the point-of care. The joint-effort is a move that seeks to leverage expertise in oncology to save lives and lower costs for patients. RAMAT GAN, Israel and BASEL, Switzerland (PRWEB) March 19, 2019 Sheba Medical Center at Tel HaShomer, the largest...

Theranos Whistleblower Tyler Shultz to Participate in Keynote Interview at DeviceTalks Boston

At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. DeviceTalks is excited to announce that Tyler Shultz will be the closing keynote speaker at DeviceTalks Boston. Shultz will take attendees behind the story that eve...

Laboratorios Farmacéuticos ROVI (ROVI) - DORIA Phase III trial hits primary endpoint

Edison Investment Research - Pharmaceuticals & healthcare - Laboratorios Farmacéuticos ROVI: Laboratorios Farmacéuticos ROVI (ROVI) has announced top-line data from the pivotal Phase III PRISMA-3 trial evaluating DORIA (ISM risperidone) in schizophrenia. DORIA achieved the primary endpoint of a statistically significant reduction (p<0.0001) in PANSS score at week 12 (both 75mg and 1...

Unite Us Raises $35 Million to Bridge the Gap Between Health and Social Care

Unite Us, the leading care coordination and outcome tracking platform connecting healthcare and social service providers, today announced $35 million in Series B funding led by Oak HC/FT, with participation from Town Hall Ventures and Define Ventures. Existing investors Scout Ventures, Luminate (part of The Omidyar Group) and New York Ventures also partici...

The Avoca Group Announces Agenda for 8th Annual Avoca Global Summit

Boston Harbor Hotel, Boston, MA, June 5-6, 2019 The Avoca Group today announced the preliminary agenda for its 8th Annual Avoca Global Summit to be held June 5-6 at the Boston Harbor Hotel in Boston, MA. The theme for this year’s Summit, “Own the Future,” focuses on the most innovative solutions for driving efficiency, improving quality, and miti...

White Oak Healthcare Finance Announces Launch of Healthcare Real Estate Investment Vehicle with New Hires

White Oak Healthcare Finance, LLC (“White Oak”) today announced it will broaden its product offering and enter the healthcare real estate investment market. White Oak hired Jeff Erhardt, Paul Nevala, Mike Treiber and John Brussard to build out the vehicle, which will initially invest up to $500MM and will focus on investments in seniors housing and ski...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks